Skip to main content
Terug
Watch Compare

PURPLE BIOTECH LTD.

Datakwaliteit: 33%
PPBT
Nasdaq Manufacturing Chemicals
€ 3,97
▼ € 0,27 (-6,29%)
Marktkapitalisatie: 6,06 M
Prijs
€ 3,97
Marktkapitalisatie
6,06 M
Dagbereik
€ 3,96 — € 4,28
52-Weeksbereik
€ 3,60 — € 29,40
Volume
14.223
Openen € 4,16
50D / 200D Gem.
€ 4,97
20,26% below
50D / 200D Gem.
€ 10,70
62,95% below

Quick Summary

Belangrijkste Punten

P/E of 0,34 — trading at a low valuation

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current RatioN/A
Interest CoverageN/A

Waardering

PE (TTM)
0,34
Boven sectorgemiddelde (-1,47)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E 0,3 -1,5
P/B — 1,6
ROE % — -53,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) 17,83 M
ROE N/A ROA N/A
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) N/A
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio N/A
Interest Coverage N/A Asset Turnover N/A
Working Capital N/A Tangible Book Value N/A
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 0,34 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield N/A
Market Cap 6,06 M Enterprise Value N/A
Per Share
EPS (Diluted TTM) N/A Revenue / Share N/A
FCF / Share N/A OCF / Share N/A
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion N/A
SBC-Adj. FCF N/A Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2021
Revenue —
Net Income 17,83 M
EPS (Diluted) —
Gross Profit —
Operating Income —
EBITDA —
R&D Expenses —
SG&A Expenses 6,11 M
D&A —
Interest Expense —
Income Tax —